Halle/Saale, June 23, 2008 -- Probiodrug AG (Probiodrug), a developer of small molecule inhibitors for the treatment of inflammatory and neurodegenerative diseases, announced today that the company has received a grant of €1.9 million from the public research funding program “KMU innovativ: Biotechnology-BioChance”, a funding program of the German Ministry of Education and Research (BMBF) to support innovative biotech SME’s.
